Analysis of mutation of the c-Kit gene and PDGFRA in gastrointestinal stromal tumors

• Published in: Experimental and therapeutic medicine Vol. 10; no. 3; pp. 1045 - 1051
• Main Authors: XU, CHUN-WEI, LIN, SHAN, WANG, WU-LONG, GAO, WEN-BIN, LV, JIN-YAN, GAO, JING-SHAN, ZHANG, LI-YING, LI, YANG, WANG, LIN, ZHANG, YU-PING, TIAN, YU-WANG
• Format: Journal Article
• Language: English
• Published: Greece D.A. Spandidos 01.09.2015; Spandidos Publications; Spandidos Publications UK Ltd
• Subjects: Biotechnology; c-Kit; Cloning; Deoxyribonucleic acid; DNA; Gastrointestinal cancer; gastrointestinal stromal tumors; Gastrointestinal tumors; gene mutation; Gene mutations; Kinases; molecular detection; Mutation; PDGFRA; Platelet-derived growth factor; Smooth muscle; Studies; Temperature; Tumors; China; Beijing China; PDGFRA; gastrointestinal stromal tumors; molecular detection; c-Kit; gene mutation
• ISSN: 1792-0981; 1792-1015
• DOI: 10.3892/etm.2015.2613

The aim of the present study was to investigate mutation status of the c-Kit gene (KIT) and PDGFRA in patients with a gastrointestinal stromal tumor (GIST). In total, 93 patients with a GIST were included in the study, in which polymerase chain reaction amplification and gene sequencing were used to detect the sequences of exons 9, 11, 13 and 17 in KIT and exons 12 and 18 in PDGFRA. KIT mutations were detected in 64 cases (68.82%), of which exon 11 mutations were detected in 56 cases (60.22%), exon 13 mutations were detected in three cases (3.23%) and one case (1.08%) was shown to have a mutation in exon 17. The most common mutation in exon 11 was a deletion, which accounted for 55.36% (31/56) of the cases, followed by a point mutation observed in 26.79% (15/56) of the cases, while an insertion (tandem repeats) was identified in 14.29% (8/56) of the cases, and 3.57% (2/56) of the exon 11 mutations were deletions associated with a point mutation. The majority of the mutations were heterozygous, with only a few homozygous mutations. Mutational analysis revealed the mutations to be more concentrated in the classic hot zone at the 5′-end, followed by the tandem repeat frame at the 3′-end. In four cases, a mutation was detected in exon 18 of PDGFRA, of which one was associated with a mutation in KIT. The remaining three cases (10.34%, 3/29) were not associated with mutations in KIT and accounted for 37.5% (3/8) of the CD117-negative GIST cases. Therefore, the majority of the GIST cases were characterized by mutations in KIT or PDGFRA, which were directly associated with the disease. Pairs of different mutations in the same exon of KIT, or KIT mutations coupled with pairs of mutations in PDGFRA, were detected in a small number of patients. Imatinib is a small molecule tyrosine kinase inhibitor and is the first line targeted treatment for GIST, resulting in markedly improved survival rates. Thus, gene mutation genotyping may provide inspiration and guidance for imatinib-based targeted cancer therapy.